Interstitial Lung Disease Induced by Anti-ERBB2 Antibody-Drug Conjugates

Drug-induced interstitial lung disease during cancer therapies: expert opinion on diagnosis and treatment

“… 21 , 22 , 23 Interestingly, deconjugated deruxtecan did not cause DIILD in animal models and the distribution of HER2-tissue expression (low level of expression in respiratory alveoli) failed to corroborate the target-dependent uptake hypothesis, likely leaving target-independent uptake of the conjugate by immune cells as the main pathogenic explanation. 9 DIILD may develop from days to months after drug administration, so late clinical manifestations do not exclude the possibility of DIILD. 4 However, the majority of ILD events are reported to occur early in the course of treatment, within the first 2 months for ICIs and in the initial 12 months with T-DXd.…”

“…6 , 7 , 8 Very recently, a review article focused on the current knowledge of the pathogenesis and epidemiologic characteristics of anti-human epidermal growth factor receptor 2 (HER2) antibody-drug conjugate (ADC)-related lung toxicity, proposing strategies for its diagnosis and treatment. 9 The authors conclude that early diagnosis and a more appropriate treatment of ADC-induced ILD may improve the therapeutic index of this relevant class of anticancer agents, allowing for a safe extension of the use of anti-HER2 ADCs across different tumour types. 9 …”

“… 9 The authors conclude that early diagnosis and a more appropriate treatment of ADC-induced ILD may improve the therapeutic index of this relevant class of anticancer agents, allowing for a safe extension of the use of anti-HER2 ADCs across different tumour types. 9 …”

Impact of Glucocorticoid Use in Oncology in the Immunotherapy Era

“…Certain types of chemotherapy (bleomycin, gemcitabine) [ 61 ] or targeted therapies, EGFR (erlotinib, gefitinib) [ 62 ], mTOR or MEK inhibitors [ 63 ], or even monoclonal antibodies targeting HER2 (especially certain new antibody-drug conjugates such as trastuzumab deruxtecan, known to cause interstitial lung disease (ILD)) can be responsible for lung toxicity [ 64 ]. In parallel to discontinuation of the implicated drug, many physicians also prescribe GCs, which can help to resolve the dyspnoeic symptoms and improve the pulmonary radiographic presentation [ 65 ].…”

Systemic Treatments for Metastatic Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Old Certainties and New Frontiers

“… 24 Several recommendations remain to be considered, including close monitoring for symptoms as well as starting steroids as soon as interstitial lung disease is suspected. 36 , 37 …”